What is the main reason IDT Australia (ASX:IDT) upgraded its FY26 guidance?

IDT Australia (ASX:IDT) upgraded its financial year 2026 outlook because the business experienced favourable trading conditions and strong operational performance across its three core manufacturing verticals.

What are the updated financial figures reported by IDT Australia (ASX:IDT)?

IDT Australia (ASX:IDT) expects unaudited FY26 revenue to increase by 16.5% year-on-year to A$16.8 million, while its earnings before interest, tax, depreciation, and amortisation (EBITDA) forecast improved significantly to negative A$943,000.

How does the new earnings outlook for IDT Australia (ASX:IDT) compare to FY25?

IDT Australia (ASX:IDT) projected an earnings recovery from FY25 actuals, with its forecasted EBITDA loss of negative $943,000 narrowing substantially from the negative A$6.3 million recorded in FY25.

What does IDT Australia (ASX:IDT) produce at its main facilities?

IDT Australia (ASX:IDT) develops and manufactures high-potency active pharmaceutical ingredients, as well as oral and injectable finished drug dose forms, out of its facilities in Boronia, Victoria.

Which regulatory approvals support the commercial operations of IDT Australia (ASX:IDT)?

IDT Australia (ASX:IDT) maintains fully cGMP-compliant manufacturing facilities that are regularly audited and approved by both the US Food and Drug Administration and the Australian Therapeutic Goods Administration.

Image for illustrative purposes only. Not a real photo.

IDT Australia upgrades FY26 revenue to $16.8M

Written by Liezl GambePublished Jul 21, 2026, 6:27 AM

IDT Australia upgraded its FY26 revenue forecast to $16.8 million, representing a 16.5% year-on-year increase.
The company projected a substantial earnings recovery, with EBITDA losses narrowing to negative $943,000.
Management cited favourable trading conditions and operational growth across its three core manufacturing verticals.

Pharmaceutical manufacturer IDT Australia (ASX:IDT) upgraded its financial year 2026 revenue guidance to $16.8 million.

The projected revenue total represents a 16.5% year-on-year increase across the business.

IDT attributed the updated financial forecast to favourable trading conditions and strong operational execution.

The company expects EBITDA to improve to negative $6.3 million in FY25.

Following the announcement, the IDT share price was up at $0.041.

IDT operates active pharmaceutical ingredient and finished dose manufacturing facilities in Boronia, Victoria.

These facilities maintain full regulatory compliance with both the US FDA and the Australian TGA.

IDT Australia upgrades FY26 revenue to $16.8M

Frequently asked questions

Assets related to this article